Regenerative Medicine in Pharma Market to Grow by 11.1% Annually Through 2027 - ResearchAndMarkets.com

The "Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), and Segment Forecast, 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027. The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The regenerative medicine in pharma market size was valued at US$29.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the forecast period (2022-2027). The market is driven by the growing prevalence of chronic diseases, genetic disorders, and cancer and technological advancements in stem-cell therapies.

Scope

• Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
• Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
• Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
• Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.
• The competitive landscape: an examination of the positioning of leading players in regenerative medicine in pharma market.

Reasons to Buy

• This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
• Accompanying the publisher's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in regenerative medicine in pharma markets.
• The report also highlights key product, therapeutic area segments.
• With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
• The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in regenerative medicine in pharma market.

Key Topics Covered:

CHAPTER 01 Executive Summary

CHAPTER 02 Market Landscape

CHAPTER 03 Regenerative Medicine in Pharma Value Chain

CHAPTER 04 Regulatory and Market Access

4.1 Differences Between Conventional Therapies and Stem Cell Therapies in Clinical Trials

4.2 US

4.2.1 Regulatory

4.2.2 Market Access

4.3 Europe

4.4 Regulation of Regenerative Medicine in the US and Europe

4.5 Japan

4.6 South Korea

CHAPTER 05 Marketed Products

5.1 Overview

5.1.1 Leading Cell-Based Immunotherapy Treatments

5.1.2 Leading Gene Therapy Treatments

5.1.3 Leading Cell-Therapies Treatment

5.1.4 Leading Tissue Engineered Products Treatments

CHAPTER 06 Regenerative Medicine Pipeline Products in the 8MM

6.1 Late-Stage Gene Therapy Products

6.2 Late-Stage Gene-Modified Cell Therapy Products

6.3 Late-Stage Cell Therapy Products

6.4 Late-Stage Tissue-Engineered Treatment

CHAPTER 07 Regenerative Medicine in Pharma Industry Analysis

7.1 Regenerative Medicine in Pharma Market Structure - PORTER's Analysis

7.2 Deals in Regenerative Medicine in Pharma

7.3 Funding in Regenerative Medicine in Pharma

CHAPTER 08 Global Regenerative Medicine in Pharma Revenue Opportunity

8.1 Global Digital Biomarkers Market

8.2 COVID-19 Pandemic

CHAPTER 09 Regenerative Medicine in Pharma Product Outlook

9.1 Regenerative Medicine in Pharma - Product Dive

9.1.1 Tissue-Engineered Products

9.1.2 Gene Therapies

9.1.3 Cell Therapies

9.1.4 Others

CHAPTER 010 Regenerative Medicine in Pharma Therapeutic Area Outlook

10.1 Regenerative Medicine in Pharma - Therapeutic Area Dive

CHAPTER 011 Regenerative Medicine in Pharma Regional Outlook

11.1 Regenerative Medicine in Pharma - Regional Deep Dive

11.1.1 North America

11.1.2 Europe

11.1.3 Asia-Pacific

11.1.4 ROW

CHAPTER 012 Trends, Drivers, and Challenges

12.1 Regenerative Medicine in Pharma - Market Trends

12.1.1 Constant Innovation in Cell Engineering Techniques:

12.1.2 Increasing Application of Gene Therapy:

12.1.3 Fast Track Approvals and Multiple Drugs in Last Stages of Pipeline

12.1.4 the Momentum Created by Allogenic Therapeutics Continues to Drive Market:

12.1.5 Increasing Applications of 3D Printing in Regenerative Medicine:

12.2 Regenerative Medicine in Pharma - Market Drivers

12.2.1 Growing Prevalence of Chronic Diseases, Genetic Disorders, and Cancer

12.2.2 Technological Advancements in Stem-Cell Therapies

12.2.3 Increased Investment by Key Players in R&D of the Regenerative Medicines

12.3 Regenerative Medicine in Pharma - Market Challenges

12.3.1 Gene Therapy

12.3.2 Cell Therapy

12.3.3 Tissue-Engineered Products and Biomaterials

CHAPTER 013 Regenerative Medicine in Pharma Market Vendor Snapshot

CHAPTER 014 Appendix

Companies Mentioned

• Novartis
• Gilead
• Amgen
• Bristol Myers-Squibb
• Bluebird bio
• Johnson & Johnson
• Biomarin
• PTC Therapeutics
• Orchard Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/47qzh8

Source: GlobalData

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005338/en/